Orlando, FL - Results of a randomized trial show a significant reduction in venous-thromboembolism (VTE) events in stroke patients receiving the low-molecular-weight (LMW) heparin enoxaparin (Lovenox, ...

The low–molecular-weight heparin enoxaparin is a safe and effective therapy to prevent symptomatic venous thromboembolism in patients undergoing chemotherapy for advanced pancreatic cancer, according ...

Oral edoxaban showed superior results to subcutaneous enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty, according to findings published in Thrombosis Journal. “In ...

Among over 17,000 patients, the more selective enoxaparin protocol was associated with a reduction in wound hematomas compared with the original standard protocol (0.3% vs 0.7%; adjusted OR 0.38, 95% ...

In the Prevention of VTE in Acutely ill Patients, Rivaroxaban Compares Favorably with Enoxaparin but Does Not Show a Consistent Net Clinical Benefit MAGELLAN study meets primary efficacy endpoints of ...

In this study, no difference in the rate of CVC-related VTE was detected between patients receiving enoxaparin and patients receiving placebo. The dose of enoxaparin used in this study proved to be ...

Aspirin alone doesn’t seem to be enough to prevent symptomatic venous thromboembolism (VTE) in the months following total hip or knee replacement for osteoarthritis, results of the CRISTAL trial ...

Oral rivaroxaban (Xarelto; Bayer/Janssen) is superior to subcutaneous enoxaparin in preventing venous thromboembolism (VTE) without increasing bleeding in patients undergoing nonmajor orthopedic ...

Surgery for hip fracture carries a high risk of venous thromboembolism, despite the use of current thromboprophylactic treatments. Fondaparinux, a synthetic pentasaccharide, is a new antithrombotic ...

Higher Risk of VTE in CKD Surgical Patients on Enoxaparin For patients with chronic kidney disease (CKD) who undergo total hip replacement (THR), the rate of major venous thromboembolism (VTE) is ...

In the randomized, placebo-controlled EXCLAIM trial, Russell Hull and colleagues evaluated the efficacy and safety of extended-duration enoxaparin (low-molecular-weight heparin). A large proportion of ...

Despite thromboprophylaxis, major knee surgery carries a high risk of venous thromboembolism. Fondaparinux, the first of a new class of synthetic antithrombotic agents, may reduce this risk. The ...